Trial Profile
Phase I clinical trial of 17-allylamino-17-demethoxy-geldananmycin (KOS-953; 17-AAG) [tanespimycin] in relapsed and relapsed refractory multiple myeloma
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2007
Price :
$35
*
At a glance
- Drugs Tanespimycin (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Jul 2007 New trial record.